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Abstract
Purpose: Quantitative analysis of cancer risk of ionising radiation as a function of dose-rate.
Materials and methods: Non-tumour dose, Dnt, deﬁned as the highest dose of radiation at which no statistically signiﬁcant
tumour increase was observed above the control level, was analysed as a function of dose-rate of radiation.
Results: An inverse correlation was found between Dnt and dose-rate of the radiation. Dnt increased 20-fold with decreasing
dose-rate from 1–10
78 Gy/min for whole body irradiation with low linear energy transfer (LET) radiation. Partial body
radiation also showed a dose-rate dependence with a 5- to 10-fold larger Dnt as dose rate decreased. The dose-rate effect was
also found for high LET radiation but at 10-fold lower Dnt levels.
Conclusions: The cancer risk of ionising radiation varies 1000-fold depending on the dose-rate of radiation and exposure
conditions. This analysis explains the discrepancy of cancer risk between A-bomb survivors and radium dial painters.
Keywords: radiation cancer risk, non-tumour dose, dose-rate
Introduction
The dose-rate of ionising radiation that humans have
been exposed to from natural to accidental radiation
sources varies over a wide range from 10
79 to 10
7
Gy/min. Radiation dose-rate affects the magnitude of
cancer risk even for the same total dose, and in
addition changes the shape of the dose-response
curve. For assessment of cancer risks of ionising
radiation resulting from different exposure condi-
tions, ideally, a set of dose response curves is needed
for each dose-rate.
Currently, the estimation of human cancer risk
from low doses of radiation is an important problem
and data have been extensively reviewed (Committee
on the Biological Effects of Ionizing Radiation
[BEIR]/National Research Council [NRC], United
Nations Scientiﬁc Committee on the Effects of Ato-
mic Radiation [UNSCEAR] 1986, 2000, National
Council on Radiological Protection and Measure-
ments [NCRP] 1980, BEIR V 1990, BEIR VII 2005,
National Radiological Protection Board [NRPB]
1995, Duport 2003). The dose and dose-rate
effectiveness factor (DDREF) for cancer risk was
determined as 2–10 depending on the target organ
(NCRP 1980, International Commission on Radi-
ological Protection [ICRP] 1991, UNSCEAR 1993,
NRPB 1995). The application of the linear non-
threshold (LNT) model, based on the apparently
linear dose-response relation of cancer mortality
obtained from extremely high dose-rate cases of A-
bomb survivors, was recommended for the estimation
of the cancer risk of low dose radiation for protection
purposes (NCRP 2001, Brenner et al. 2003, BEIR
VII 2005, ICRP 2006); however, the LNT model was
questioned for its validity from experimental and
epidemiological evidence (Kondo 1993, Acade ´mie
des Sciences 1997, Tanooka 2001, Tubiana et al.
2006, Feinendegen et al. 2007). The history of the
LNT model explains how the idea of a tolerance dose
was changed to the linearity concept by incorporating
the view of the geneticist (Calabrese 2009). However,
a recent review of new biological and epidemiological
data still adopted the LNT model (Mullenders et al.
2009). Whatever the model, there exists both linear
and threshold type dose-response relations for
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DOI: 10.3109/09553002.2010.545862radiation-induced cancers in experimental and epi-
demiological data. For example, the shape of the
dose-response curve for cancer incidence may con-
form to a linear type for leukemia and solid cancers in
A-bomb survivors (Chomentowski et al. 2000), while
it is non-linear, or even threshold-like, for bone
tumours in radium dial painters (Rowland et al.
1978) and liver tumours in thorotrast-injected
patients (Anderson and Storm 1992). This discre-
pancy remained still to be explained.
In a previous study, non-tumour dose, Dnt, was
deﬁned as the highest dose at which no statistically
signiﬁcant tumour increase was observed above the
control level. It was proposed as a measure of the
upper limit of radiation dose for non-detectable
cancer and Dnt values were surveyed for in the
literature. The results showed that Dnt depended on
exposure conditions, i.e., acute, protracted, and
chronic exposures for whole body and partial body
radiation for either low linear energy transfer (LET)
or high LET radiation, respectively, with an inverse
correlation between Dnt and dose-rate (Tanooka
2001). The present study aimed to show the dose-
rate dependence of Dnt more quantitatively as a
function of the dose-rate of radiation.
Data base
Dose-response data covering ionising radiation ex-
posures from non-tumour to tumour-inducing doses
were surveyed in the literature and are listed in
Table I. These include Dnt values, and correspond-
ing dose-rates of radiation in mice, rats, dogs, and
humans with different tumour types obtained under
different exposure conditions. Data in the previous
study (Tanooka 2001) and additional data were used
for the present quantitative analysis. The data
numbers in the previous study were unchanged for
the convenience of comparison.
Estimation of dose-rate
The values for the dose-rate were obtained from each
published paper. For external radiation, the dose-
rate was clearly presented in the literature either for
whole body or partial body exposures. However, for
internal radiation from radioactive nuclides, the
estimation of dose-rate required assumptions and
calculations depending on whether internal radio-
active nuclides were distributed in the whole body or
deposited partially in the target organ. Moreover, the
radioactivity decayed with time and the radioactive
nuclide was cleared from the body. In the present
analysis, an average dose-rate was estimated from the
total dose divided by the exposure time or, when a
decay curve was available, an average dose-rate over
the 70% decay time was taken. This calculation may
have resulted in a lower estimate of dose-rate and a
higher estimate of Dnt, provided that the radiation
dose given only in the ﬁrst half of the exposure time
was effective for tumour induction. However, correc-
tion for this gave little change in the plot of Dnt
versus dose-rate on a bi-logarithmic scale.
Results and discussion
Numerical values for Dnt and corresponding dose-
rates obtained from various tumour systems are
listed in Table I. These values were divided into four
groups, i.e., whole body irradiation with low LET
and high LET radiation and partial body irradiation
with low LET and high LET radiation, respectively.
Figure 1 shows a plot of Dnt against dose-rate on a
bi-logarithmic scale and regression lines ﬁtted to the
data for dose-rates below 1 Gy/min. A clear dose-rate
dependence of Dnt is seen for the four exposure
patterns.
For whole body irradiation with low LET radia-
tion, Dnt increased when lowering the dose-rate
below 1 Gy/min and became 20-fold higher at 10
78
Gy/min (Figure 1a). Only one point for humans was
available for the high dose-rate 10
7 Gy/min, based on
the assumption that the A-bomb radiation was
delivered in 1 msec. It appeared that Dnt is constant
for dose-rates between 1 and 10
7 Gy/min, as shown
by the horizontal line in Figure 1a. For high LET
irradiation of the whole body, there were few data
available, but the dose-rate dependence of Dnt was
seen at a level about 10- to 20-fold lower than for low
LET radiation, although high LET radiation has
been considered to have no dose-rate effect.
For partial body irradiation, the dose-rate depen-
dence of Dnt was again seen for both low LET and
high LET radiation (Figure 1b). Dose-response data
for dose-rates higher than 10 Gy/min were not
available in the literature. The Dnt level of partial
body radiation was about 5- to 10-fold higher for low
LET radiations and 3- to 5-fold higher for high LET
radiations than those for whole body radiation.
At an extremely high dose-rate for whole body
radiation, A-bomb survivor data (Shimizu et al. 1990)
gave a Dnt of 0.2 Gy for leukemia mortality; while
mouse data from nuclear detonation experiments at
similar dose-rates showed a signiﬁcant increase in
pituitary and Harderian gland tumours at the same
dose, 0.2 Gy (Furth et al. 1954). Consequently,
humans seem to be more tolerant to radiation than
mice and the regression lines drawn from animal data
may under-estimate Dnt for humans. Dnt values, for
partial body high-LET radiation to radium dial
painters (Rowland et al. 1973, 1978) and thoro-
trast-injected patients (Anderson and Storm 1992),
were much larger than those for experimental animals
(Figure 1b), again indicating a higher radiation
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648 H. Tanookatolerance of humans. The other extreme case is the
absence of thymic lymphoma induction in mice
irradiated at 2610
75 mGy/min with a total whole
body dose of 7.2 Gy;whereas, acute radiation given in
four fractions with the same total dose yielded a 90%
tumour incidence (Ina et al. 2005), as was originally
found in the early experiments of Kaplan and Brown
(1952).
Fractionation of radiation dose at a ﬁxed dose-rate
within a deﬁned time interval lowers cancer in-
cidence, as shown in the induction of skin tumours
by local irradiation in rats (Burns et al. 1973, 1975,
1993). However, fractionation necessarily involves
repetitive irradiations, which results in a tumour-
enhancing effect as seen for mouse thymic lympho-
ma induction (Kaplan and Brown 1952) and also in
mouse skin tumour induction (Ootsuyama and
Tanooka 1991). It should be noted that the repetitive
treatment is efﬁcient for chemical induction of
tumours. This contradictory effect should be con-
sidered in analysing the dose-rate effect.
Figure 2 summarises the regression lines for the
four exposure patterns. These four lines are thought
to cover all possible radiation exposure cases and
hopefully to serve as a measure of cancer risk for any
exposure situation in the human environment. Total
whole body radiation doses received over 70 years
from the natural environment high background
radiation areas in Kerala, India (Nair et al. 1999)
and Yanjiang, China (Chen and Wei 1991) are much
smaller than Dnt for the respective dose-rates in each
district (Figure 2). The radiation dose to astronauts
in space (Horneck et al. 2003) is also shown in
Figure 2, indicating a value close to Dnt even with a
radiation shield. The cancer risk of medical exam-
ination with computer tomography (CT) has been
analysed on the basis of whole-body data of A-bomb
survivors (Berrington de Gonzalez and Darby 2004);
however, this risk should have been analysed on the
basis of partial body data. The highest possible dose
for CT was still far lower than the corresponding Dnt.
Recently, Tubiana et al. (in press) reported the dose
response of second cancer incidence after radiation
therapy with a Dnt of about 1 Gy based on a large
number of patients. This study provides important
data on human exposure to partial body low LET
radiation.
There are differences in the radiation sensitivity of
tumour induction, depending on the type of tumour
and host sensitivity. Dnt is much smaller in repair-
deﬁcient mice compared to wild-type mice (Ishii-
Ohba et al. 2007), indicating that the regression lines
represent the wild-type character of the hosts.
Currently, a large scale life-time exposure of mice
to external g rays with graded dose-rates from 1–800
mGy per 22 h a day (dose-rate: 7.5610
76 7
6610
73 Gy/min, total dose for 3 years: 1.1 – 876
Gy) together with control mice is being conducted
and chromosome aberration data have been reported
(Tanaka et al. 2009). Such experiments will give
more accurate data for the effect of dose-rate on
tumour induction. Further data will be needed to
cover the whole dose-rate range for tumour
induction.
Figure 1. Non-tumour dose, Dnt, plotted as a function of the dose-rate of radiation. (a) Whole body radiation. (b) Partial body radiation.
Block symbols, low LET; open symbols, high LET. Mouse (., ); rat (~, ~); dog (&, ¤); human, whole-body low LET (H); and human,
partial body high LET (h). Arrows indicate Dnt higher. Numbers afﬁxed to each point are data numbers (see Table I).
Non-tumour dose and dose-rate 649Summary
Meta-analysis ofthenon-tumourdose,Dnt,ofionising
radiation showed a clear dependence on dose-rate
over a wide range for four exposure conditions, i.e.,
whole body irradiation with low LET or high LET
radiation and partial body irradiation with low LET or
high LET radiation. From the regression lines for the
relation between dose-rate and Dnt, a cancer risk or
tolerance level of radiation could be estimated for a
variety of exposure conditions. An apparent discre-
pancy in radiation-induced tumour data could be
explained in terms of dose-rate.
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